SXTP (60 Degrees Pharmaceuticals Inc.) stock: $0.59, $2.1M market cap, $1.0M cash, $1.2M EV, $2.1M fully diluted market cap. Next expected readout: Feb-27. Lead program: Tafenoquine 100mg (Chronic Babesiosis), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Approved · ActiveModality: small molecule (8-aminoquinoline; oral)
Partnerships Licensed from the U.S. Army (USAMMDA), covering all therapeutic uses except radical cure of symptomatic vivax malaria; cooperative R&D agreement with the U.S. Army supporting original Arakoda NDA. Babesiosis use licensed from Tufts Medical Center (Dec 2024)
Indications
Malaria prevention(Approved)
Babesiosis (hospitalized patients, with standard of care)(Phase 2)
Status note Arakoda FDA-approved 2018 for malaria prevention. Double-blind, placebo-controlled trial (NCT06207370) of the Arakoda regimen with standard of care in hospitalized babesiosis patients: first patient randomized June 25, 2024; 19 patients completed. Veterinary pilot studies (canine babesiosis at NC State; equine Theileria) in planning.
Celgosivir
Preclinical · ActiveModality: small molecule (host-targeted glucosidase inhibitor)
Partnerships Licensed from National University of Singapore / Singapore Health Services (patent rights for celgosivir dosing regimens for dengue)
Indications
Dengue fever(Preclinical)
Respiratory viruses (COVID-19, RSV)(Preclinical)
Status note Prior Phase II development by other sponsors (HIV, hepatitis C, dengue in 700+ patients; dengue trial showed safety with sub-powered viral-load reduction). No active company-sponsored clinical development; company holds dengue dosing patents and filed/licensed patents for respiratory virus applications.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.